Compare AU
Compare CURE vs. HLTH
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the VanEck Global Healthcare Leaders ETF (HLTH). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | HLTH | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 78 | 59 |
Median incremental investment | $640.11 | $537.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,290.30 | $1,482.95 |
Average age group | > 35 | > 35 |
Key Summary
CURE | HLTH | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 27.78m in AUM and 125 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | HLTH.AX was created on 2020-09-08 by VanEck. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investment returns before fees and other costs which track the performance of the Reference Index in Australian dollars. |
Top 3 holdings | Natera Inc (2.73 %) Alnylam Pharmaceuticals Inc (2.65 %) Vertex Pharmaceuticals Inc (2.64 %) | Chugai Pharmaceutical Co Ltd (2.70 %) Corcept Therapeutics Inc (2.44 %) Shionogi & Co Ltd (2.41 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Health Care (100.00 %) Other (9.88 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (68.78 %) Japan (13.50 %) Denmark (7.34 %) |
Management fee | 0.45 % | 0.45 % |
Key Summary
CURE | HLTH | |
|---|---|---|
Issuer | Global X | VanEck |
Tracking index | S&P Biotechnology Select Industry | MarketGrader Developed Markets ex-Australia Health Care Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.45 % |
Price | $44.08 | $11.30 |
Size | $28.994 million | $47.269 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 0.58 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 09/09/2020 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | HLTH | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 78 | 59 |
Median incremental investment | $640.11 | $537.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,290.30 | $1,482.95 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | HLTH | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | HLTH |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |